swainsonine has been researched along with cyclin d1 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dou, K; Gong, Z; Ji, R; Liu, W; Tao, K; Wang, T; Wang, X; You, N | 1 |
1 other study(ies) available for swainsonine and cyclin d1
Article | Year |
---|---|
Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Astragalus propinquus; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Fas Ligand Protein; fas Receptor; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Paclitaxel; Swainsonine | 2012 |